OBJECTIVE: To determine the prevalence and associated mortality of well-defined neurologic diagnoses among patients with coronavirus disease 2019 (COVID-19), we prospectively followed hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients and recorded new neurologic disorders and hospital outcomes. METHODS: We conducted a prospective, multicenter, observational study of consecutive hospitalized adults in the New York City metropolitan area with laboratory-confirmed SARS-CoV-2 infection. The prevalence of new neurologic disorders (as diagnosed by a neurologist) was recorded and in-hospital mortality and discharge disposition were compared between patients with COVID-19 with and without neurologic disorders. RESULTS: Of 4,491 patients with COVID-19 hospitalized during the study timeframe, 606 (13.5%) developed a new neurologic disorder in a median of 2 days from COVID-19 symptom onset. The most common diagnoses were toxic/metabolic encephalopathy (6.8%), seizure (1.6%), stroke (1.9%), and hypoxic/ischemic injury (1.4%). No patient had meningitis/encephalitis or myelopathy/myelitis referable to SARS-CoV-2 infection and 18/18 CSF specimens were reverse transcriptase PCR negative for SARS-CoV-2. Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment (SOFA) scores (all p < 0.05). After adjusting for age, sex, SOFA scores, intubation, history, medical complications, medications, and comfort care status, patients with COVID-19 with neurologic disorders had increased risk of in-hospital mortality (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.17-1.62, p < 0.001) and decreased likelihood of discharge home (HR 0.72, 95% CI 0.63-0.85, p < 0.001). CONCLUSIONS: Neurologic disorders were detected in 13.5% of patients with COVID-19 and were associated with increased risk of in-hospital mortality and decreased likelihood of discharge home. Many observed neurologic disorders may be sequelae of severe systemic illness.
OBJECTIVE: To determine the prevalence and associated mortality of well-defined neurologic diagnoses among patients with coronavirus disease 2019 (COVID-19), we prospectively followed hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients and recorded new neurologic disorders and hospital outcomes. METHODS: We conducted a prospective, multicenter, observational study of consecutive hospitalized adults in the New York City metropolitan area with laboratory-confirmed SARS-CoV-2 infection. The prevalence of new neurologic disorders (as diagnosed by a neurologist) was recorded and in-hospital mortality and discharge disposition were compared between patients with COVID-19 with and without neurologic disorders. RESULTS: Of 4,491 patients with COVID-19 hospitalized during the study timeframe, 606 (13.5%) developed a new neurologic disorder in a median of 2 days from COVID-19 symptom onset. The most common diagnoses were toxic/metabolic encephalopathy (6.8%), seizure (1.6%), stroke (1.9%), and hypoxic/ischemic injury (1.4%). No patient had meningitis/encephalitis or myelopathy/myelitis referable to SARS-CoV-2 infection and 18/18 CSF specimens were reverse transcriptase PCR negative for SARS-CoV-2. Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment (SOFA) scores (all p < 0.05). After adjusting for age, sex, SOFA scores, intubation, history, medical complications, medications, and comfort care status, patients with COVID-19 with neurologic disorders had increased risk of in-hospital mortality (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.17-1.62, p < 0.001) and decreased likelihood of discharge home (HR 0.72, 95% CI 0.63-0.85, p < 0.001). CONCLUSIONS: Neurologic disorders were detected in 13.5% of patients with COVID-19 and were associated with increased risk of in-hospital mortality and decreased likelihood of discharge home. Many observed neurologic disorders may be sequelae of severe systemic illness.
Authors: James J Sejvar; Katrin S Kohl; Jane Gidudu; Anthony Amato; Nandini Bakshi; Roger Baxter; Dale R Burwen; David R Cornblath; Jan Cleerbout; Kathryn M Edwards; Ulrich Heininger; Richard Hughes; Najwa Khuri-Bulos; Rudolf Korinthenberg; Barbara J Law; Ursula Munro; Helena C Maltezou; Patricia Nell; James Oleske; Robert Sparks; Priscilla Velentgas; Patricia Vermeer; Max Wiznitzer Journal: Vaccine Date: 2010-06-18 Impact factor: 3.641
Authors: Allan R Tunkel; Carol A Glaser; Karen C Bloch; James J Sejvar; Christina M Marra; Karen L Roos; Barry J Hartman; Sheldon L Kaplan; W Michael Scheld; Richard J Whitley Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079
Authors: Ross W Paterson; Rachel L Brown; Laura Benjamin; Ross Nortley; Sarah Wiethoff; Tehmina Bharucha; Dipa L Jayaseelan; Guru Kumar; Rhian E Raftopoulos; Laura Zambreanu; Vinojini Vivekanandam; Anthony Khoo; Ruth Geraldes; Krishna Chinthapalli; Elena Boyd; Hatice Tuzlali; Gary Price; Gerry Christofi; Jasper Morrow; Patricia McNamara; Benjamin McLoughlin; Soon Tjin Lim; Puja R Mehta; Viva Levee; Stephen Keddie; Wisdom Yong; S Anand Trip; Alexander J M Foulkes; Gary Hotton; Thomas D Miller; Alex D Everitt; Christopher Carswell; Nicholas W S Davies; Michael Yoong; David Attwell; Jemeen Sreedharan; Eli Silber; Jonathan M Schott; Arvind Chandratheva; Richard J Perry; Robert Simister; Anna Checkley; Nicky Longley; Simon F Farmer; Francesco Carletti; Catherine Houlihan; Maria Thom; Michael P Lunn; Jennifer Spillane; Robin Howard; Angela Vincent; David J Werring; Chandrashekar Hoskote; Hans Rolf Jäger; Hadi Manji; Michael S Zandi Journal: Brain Date: 2020-10-01 Impact factor: 13.501
Authors: Carlos Manuel Romero-Sánchez; Inmaculada Díaz-Maroto; Eva Fernández-Díaz; Álvaro Sánchez-Larsen; Almudena Layos-Romero; Jorge García-García; Esther González; Inmaculada Redondo-Peñas; Ana Belén Perona-Moratalla; José Antonio Del Valle-Pérez; Julia Gracia-Gil; Laura Rojas-Bartolomé; Inmaculada Feria-Vilar; María Monteagudo; María Palao; Elena Palazón-García; Cristian Alcahut-Rodríguez; David Sopelana-Garay; Yóscar Moreno; Javaad Ahmad; Tomás Segura Journal: Neurology Date: 2020-06-01 Impact factor: 9.910
Authors: Isaac H Solomon; Erica Normandin; Shamik Bhattacharyya; Shibani S Mukerji; Kiana Keller; Ahya S Ali; Gordon Adams; Jason L Hornick; Robert F Padera; Pardis Sabeti Journal: N Engl J Med Date: 2020-06-12 Impact factor: 91.245
Authors: Susanne Rabady; Johann Altenberger; Markus Brose; Doris-Maria Denk-Linnert; Elisabeth Fertl; Florian Götzinger; Maria de la Cruz Gomez Pellin; Benedikt Hofbaur; Kathryn Hoffmann; Renate Hoffmann-Dorninger; Rembert Koczulla; Oliver Lammel; Bernd Lamprecht; Judith Löffler-Ragg; Christian A Müller; Stefanie Poggenburg; Hans Rittmannsberger; Paul Sator; Volker Strenger; Karin Vonbank; Johannes Wancata; Thomas Weber; Jörg Weber; Günter Weiss; Maria Wendler; Ralf-Harun Zwick Journal: Wien Klin Wochenschr Date: 2021-12-01 Impact factor: 1.704
Authors: Verena Rass; Ronny Beer; Alois Josef Schiefecker; Mario Kofler; Anna Lindner; Philipp Mahlknecht; Beatrice Heim; Victoria Limmert; Sabina Sahanic; Alex Pizzini; Thomas Sonnweber; Ivan Tancevski; Christoph Scherfler; Laura Zamarian; Rosa Bellmann-Weiler; Günter Weiss; Atbin Djamshidian; Stefan Kiechl; Klaus Seppi; Judith Loeffler-Ragg; Bettina Pfausler; Raimund Helbok Journal: Eur J Neurol Date: 2021-05-03 Impact factor: 6.288
Authors: Elizabeth Carroll; Kara R Melmed; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Ariane Lewis Journal: Seizure Date: 2021-05-17 Impact factor: 3.414
Authors: John F Fullard; Hao-Chih Lee; Georgios Voloudakis; Shengbao Suo; Behnam Javidfar; Zhiping Shao; Cyril Peter; Wen Zhang; Shan Jiang; André Corvelo; Heather Wargnier; Emma Woodoff-Leith; Dushyant P Purohit; Sadhna Ahuja; Nadejda M Tsankova; Nathalie Jette; Gabriel E Hoffman; Schahram Akbarian; Mary Fowkes; John F Crary; Guo-Cheng Yuan; Panos Roussos Journal: Genome Med Date: 2021-07-19 Impact factor: 15.266
Authors: Michelle Elena Schober; Courtney Leigh Robertson; Mark Stephen Wainwright; Juan David Roa; Ericka Linn Fink Journal: Neurocrit Care Date: 2021-06-28 Impact factor: 3.210
Authors: Miguel García-Grimshaw; Erwin Chiquete; Amado Jiménez-Ruiz; José de Jesús Vidal-Mayo; Samara Lissete Grajeda-González; María de Los Ángeles Vargas-Martínez; Liz Nicole Toapanta-Yanchapaxi; Sergio Iván Valdés-Ferrer; Oswaldo Alan Chávez-Martínez; Osvaldo Alexis Marché-Fernández; Ana Itiel Jiménez-Ávila; Carlos Cantú-Brito; Fernando Daniel Flores-Silva Journal: J Acad Consult Liaison Psychiatry Date: 2021-07-06